Pure Global
NCT03204981

Intramural Needle Ablation for the Treatment of Refractory Ventricular Arrhythmias

Vivek Reddy·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ventricular Arrythmia
Drug/Device/Intervention
Intramural Needle Ablation
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Vivek Reddy
Funder
Icahn School of Medicine at Mount Sinai
Location
New York, United States of America
Timeline & enrollment
Phase
N/A
Start date
Oct 17, 2017
End date
Apr 20, 2021
Enrollment
52 participants
Primary outcome

Number of Participants Who Had Freedom From Ventricular Arrhythmia at 6 Months

Summary

This study will examine the safety and efficacy of intramural needle ablation (INA) in the
 treatment of intramural ventricular arrhythmias in patients for whom standard RF ablation has
 been unsuccessful. The clinical team hypothesize that the increased current density and
 improved rates of transmural lesion creation seen with intramural needle ablation will lead
 to successful arrhythmia termination with minimal or no increased risk of complication.

ICD-10 classifications
Ventricular tachycardiaLeft ventricular failureVentricular septal defectCardiomyopathy, unspecifiedCardiac arrhythmia, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03204981
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT03204981 through Pure Global AI's free database. This phase not specified trial is sponsored by Vivek Reddy and is currently Completed. The study focuses on Ventricular Arrythmia. Target enrollment is 52 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.